To further compare the prognostic value of ER expression in CTCs and corresponding IHC results in response to endocrine therapy, we analyzed the data from patients whose primary tumor or metastatic IHC results, CTCs, and the first-line endocrine therapy efficacy when received CTC detection were available. The gene discussed is ESR1; the disease is neoplasm.